Migraine. Diseases of the nervous system/Episodic and paroxysmal disorders
Conditions
Interventions
Intervention 1: Enalapril, 5 mg tablet, twice a day for 2 months. Intervention 2: Oral placebo tablet, twice a day for 2 months.
Treatment - Drugs
Placebo
Enalapril, 5 mg tablet, twice a day for 2 months
Oral placebo tablet, twice a day for 2 months
Sponsors
Isfahan University of Medical Sciences, Applied Physiology Research Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion Criteria: having more than three migraine attacks per month during the last 3 months, having more than 3 migraine attacks during the baseline period, debut of migraine at least one year prior to study, start of migraine before age 50 years Exclusion Criteria: Having cardiovascular (endothelial dysfunction) risk factors, undistinguishable headache interval from migraine, chronic tension-type headache or other headache occurring on more than 15 days per month, pregnancy, breast feeding, inability to use contraceptives, presence of heart conduction block on ECG or significant ECG abnormality, presence of current or previous asthma, diabetes, decreased hepatic or renal function, hypersensitivity to active substance, significant psychiatric illness, use of daily migraine prophylactics less than 4 weeks prior to study, having tried more than or equal to three prophylactic drugs against migraine during the last 10 years, previous use of Enalapril in adequate doses, previous discontinuation of Enalapril due to side effects, current use of antihypertensive medication, subjects requiring detoxification from acute medication (Ergotamines, Opioids), consistently failure to respond to any acute migraine medication, alcohol or illicit drug dependence
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical status improvement. Timepoint: before intervention/1 month later/2 months later. Method of measurement: Questionnaire.;Endothelial dysfunction recovery. Timepoint: before intervention/2 months later. Method of measurement: FMD with high resolution Bmode Ultrasonographic system/NOx with Greiss method/CRP with ELISA. | — |
Secondary
| Measure | Time frame |
|---|---|
| Headache frequencies. Timepoint: Before intervention,1 month, 2 month. Method of measurement: Questionnaire.;Headache durations. Timepoint: Before intervention,1 month, 2 month. Method of measurement: Questionnaire.;Headache severity. Timepoint: Before intervention,1 month, 2 month. Method of measurement: Questionnaire.;FMD Index. Timepoint: Before intervention,2 months later. Method of measurement: High resolution Bmode Ultrasonography.;Level of CRP. Timepoint: Before intervention,2 months later. Method of measurement: ELISA.;NOx. Timepoint: before intervention,2 months later. Method of measurement: Greiss method. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactShaghayegh Haghjooi-e-javanmard
Isfahan University of Medical Sciences
Outcome results
None listed